• Publications
  • Influence
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
BACKGROUND Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well tolerated with positiveExpand
  • 746
  • 36
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
OBJECTIVES The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients. BACKGROUND Although a variety of prognostic markers have beenExpand
  • 718
  • 35
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
IMPORTANCE Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preservedExpand
  • 758
  • 26
A standardized definition of ischemic cardiomyopathy for use in clinical research.
OBJECTIVES We sought to evaluate the association between the extent of coronary artery disease (CAD) and survival in patients with symptomatic heart failure (HF) and to create the most prognosticallyExpand
  • 441
  • 24
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
BACKGROUND Previous studies of the prognosis of patients with heart failure due to cardiomyopathy categorized patients according to whether they had ischemic or nonischemic disease. The prognosticExpand
  • 878
  • 23
Diuretic strategies in patients with acute decompensated heart failure.
BACKGROUND Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS In a prospective,Expand
  • 706
  • 23
Decision Making in Advanced Heart Failure: A Scientific Statement From the American Heart Association
Shared decision making for advanced heart failure has become both more challenging and more crucial as duration of disease and treatment options have increased. High-quality decisions are chosen fromExpand
  • 456
  • 22
Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure.
The goal of this study was to examine the frequency of mitral regurgitation (MR) in patients with left ventricular (LV) systolic dysfunction and to relate its presence and severity to long-termExpand
  • 568
  • 21
Ultrafiltration in decompensated heart failure with cardiorenal syndrome.
BACKGROUND Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety ofExpand
  • 589
  • 19
Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study
Background— Galectin-3 is a soluble ß-galactoside–binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes inExpand
  • 194
  • 16